Podcasts about vaxine

Text us here! Hersh, the folks are going to feel valued after today. We spent time giving advice to the ladies on what to buy their men for Christmas. Most of the items we discussed were given a green light by the men in Studio 18. We also ate a fruitcake on air and were persuasive enough to get the Emma-fluencer and Loretta to chaw (big word for chew in the past tense) on some of the festive cake. In the end the Chips had a disastrous day discussing an overweight aunt of theirs named Vaxine or Vaccine for short.... Enjoy! Support the showConnect with us at https://www.podnme.org/https://youtube.com/@devinbirdsongEmail devin@podnme.orgFollow us on Instagram @podn_mePersonalities on Pod'N MePastor: Devin BirdsongDeacon: Dustin WakleySongleader: Brad CottrellHershall: Jud IngramNews Anchor, Dink Burbank: Josh SmithGen Z Boy: Brooks Birdsong

Today in the Creator's Lab, Tony Dang joins Elixir Wizards Sundi Myint and Owen Bickford to break down his journey of creating a local-first, offline-ready to-do app using Phoenix LiveView, Svelte, and CRDTs (Conflict-free Replicated Data Types). Tony explains why offline functionality matters and how this feature can transform various apps. He shares insights on different libraries, algorithms, and techniques for building local-first experiences and highlights the advantages of Elixir and Phoenix LiveView. Tony also shares his go-to tools, like Inertia.js for connecting Phoenix backends with JavaScript frontends, and favorite Elixir packages like Oban, Joken, and Hammer, offering a toolkit for anyone building powerful, adaptable applications. Topics discussed in this episode: Tony Dang's background from mechanical engineer to web developer Building an offline-enabled to-do app with Phoenix LiveView and Svelte CRDTs: Conflict-free Replicated Data Types for merging changes offline How to make a LiveView app work offline Sending full state updates vs. incremental updates for performance optimization Inspiring others through open-source projects and community contributions Learning vanilla Phoenix and Channels to understand LiveView better Handling stale CSRF tokens when reconnecting to a LiveView app offline Exploring service workers and browser APIs for managing offline connectivity Balancing the use of JavaScript and Elixir in web development Fostering a supportive and inspiring Elixir community Links mentioned: Working in Elevators: How to build an offline-enabled, real-time todo app (https://www.youtube.com/watch?v=PX9-lq0LL9Q) w/ LiveView, Svelte, & Yjs Tony's Twitter: https://x.com/tonydangblog https://liveview-svelte-pwa.fly.dev/ https://github.com/tonydangblog/liveview-svelte-pwa CRDT: https://en.wikipedia.org/wiki/Conflict-freereplicateddatatype PWA: https://en.wikipedia.org/wiki/Progressivewebapp https://github.com/josevalim/sync https://github.com/sveltejs/svelte https://github.com/woutdp/livesvelte https://github.com/yjs/yjs https://github.com/satoren/yex https://github.com/y-crdt/y-crdt https://linear.app/ https://github.com/automerge/automerge https://hexdocs.pm/phoenix/1.4.0-rc.1/presence.html Vaxine, the Rich CRDT Database for ElixirPhoenix Apps (https://www.youtube.com/watch?v=n2c5eWIfziY) | James Arthur | Code BEAM America 2022 https://github.com/electric-sql/vaxine Hybrid Logical Clocks https://muratbuffalo.blogspot.com/2014/07/hybrid-logical-clocks.html https://en.wikipedia.org/wiki/256(number) CSRF Tokens in LiveView https://hexdocs.pm/phoenixliveview/Phoenix.LiveView.html#getconnectparams/1 https://hexdocs.pm/phoenix/channels.html Authentication with Passkeys (https://www.youtube.com/playlist?list=PL8lFmBcH3vX-JNIgxW3THUy7REthSRFEI) Talk by Tony https://www.meetup.com/dc-elixir/ https://github.com/rails/rails https://github.com/facebook/react-native https://github.com/vuejs https://github.com/laravel/laravel https://hexdocs.pm/phoenixliveview/js-interop.html https://github.com/inertiajs https://github.com/inertiajs/inertia-phoenix https://savvycal.com/ https://github.com/wojtekmach/req https://github.com/oban-bg/oban https://github.com/joken-elixir/joken https://github.com/ExHammer/hammer Special Guest: Tony Dang.

GUEST 1 OVERVIEW: Mark Latham is an Australian politician and media commentator, currently serving as the leader of One Nation in the New South Wales Legislative Council. He previously served as the leader of the Australian Labor Party and leader of the opposition from December 2003 to January 2005, leading the party to defeat at the 2004 federal election. After leaving parliament in 2005, Mark was a columnist for various newspapers. He is the author of 13 books, including Civilising Global Capital (1998), The Latham Diaries (2005), Outsiders (2017) and Take Back Australia (2018). Against the media orthodoxy, in 2015 he became well known as an early and strong supporter of Donald Trump in his bid for the US Presidency. Mark is one of Australia's leading advocates of ‘outsider' politics. He strongly opposes the impact of political correctness and identity politics on public debate, freely speaking his mind on a range of issues. GUEST 2 OVERVIEW: Dr Nikolai Petrovsky is Founder and Research Director of Vaxine, an Adelaide-based biotechnology company focused on vaccine development. He has been awarded over 50 million dollars from the US National Institutes of Health for his vaccine research. He has authored over 200 peer-reviewed research papers and is an inventor on multiple vaccine patents. In 2020, he developed the Covax-19/SpikoGen® vaccine against COVID-19 that in October 2021 received authorization in Iran, making it the first recombinant protein COVID-19 vaccine in the world to receive regulatory approval, and the first Australian-developed human vaccine in the last 40 years to achieve approval.

Nikolai Petrovsky – a professor & vaccine inventor – examined advanced computer models of animal ACE2 receptors as part of an investigation into the real origins of COVID-19. He uncovered new details that appear to conflict with the idea that SARS-CoV-2 crossed to humans through bats. One key finding is the presence of the Furin Cleavage Site, which is unique to SARS-CoV-2. Despite theories of mutation or recombination, the origins of this site remain unclear. The spike protein of SARS-CoV-2 is highly similar to that of a coronavirus found in pangolins, leading to speculation that the pangolin may have played a role. The research appears to suggest that the virus was already adapted to infect humans at the start of the pandemic, as it bound most strongly to human ACE2 receptors compared to other animal receptors studied. Professor Nikolai Petrovsky, founder and research director of Vaxine, is a world-renowned expert in vaccine development and immunology. He developed Covax-19 / SpikoGen® vaccine that was approved for use in Iran in October 2021, becoming the first successful human vaccine developed in Australia in the last 40 years. Find his company at https://vaxine.net 「 SPONSORED BY 」 • PALEOVALLEY - "Paleovalley has a wide variety of extraordinary products that are both healthful and delicious,” says Dr. Drew. "I am a huge fan of this brand and know you'll love it too!” Get 15% off your first order at https://drdrew.com/paleovalley • THE WELLNESS COMPANY - Counteract harmful spike proteins with TWC's Signature Series Spike Support Formula containing nattokinase and selenium. Learn more about TWC's supplements at https://twc.health/drew • BIRCH GOLD - Don't let your savings lose value. You can own physical gold and silver in a tax-sheltered retirement account, and Birch Gold will help you do it. Claim your free, no obligation info kit from Birch Gold at https://birchgold.com/drew • GENUCEL - Using a proprietary base formulated by a pharmacist, Genucel has created skincare that can dramatically improve the appearance of facial redness and under-eye puffiness. Genucel uses clinical levels of botanical extracts in their cruelty-free, natural, made-in-the-USA line of products. Get an extra discount with promo code DREW at https://genucel.com/drew 「 MEDICAL NOTE 」 The CDC states that COVID-19 vaccines are safe, effective, and reduce your risk of severe illness. You should always consult your personal physician before making any decisions about your health.  「 ABOUT the SHOW 」 Ask Dr. Drew is produced by Kaleb Nation (https://kalebnation.com) and Susan Pinsky (https://twitter.com/firstladyoflove). This show is for entertainment and/or informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment. 「 WITH DR. KELLY VICTORY 」 Dr. Kelly Victory MD is a board-certified trauma and emergency specialist with over 30 years of clinical experience. She served as CMO for Whole Health Management, delivering on-site healthcare services for Fortune 500 companies. She holds a BS from Duke University and her MD from the University of North Carolina. Follow her at https://earlycovidcare.org and https://twitter.com/DrKellyVictory. 「 ABOUT DR. DREW 」 For over 30 years, Dr. Drew has answered questions and offered guidance to millions through popular shows like Celebrity Rehab (VH1), Dr. Drew On Call (HLN), Teen Mom OG (MTV), and the iconic radio show Loveline. Now, Dr. Drew is opening his phone lines to the world by streaming LIVE from his home studio. Watch all of Dr. Drew's latest shows at https://drdrew.tv Learn more about your ad choices. Visit megaphone.fm/adchoices

On this episode: We are joined by Prof. Nikolai Petrovsky, who invented an Australian COVID vaccine and is one of the unsung heroes of the pandemic.   Prof. Petrovsky is a renowned researcher in the field of immunology, endocrinology and vaccine development. He is highly credentialled and regarded in the field of vaccine innovation and development, which led him to establishing the successful Australian biotechnology company, Vaxine, which was founded in 2002 and in which Prof. Petrovsky is the Chairman and Research Director.    At the outbreak of the pandemic, Prof. Petrovsky channeled his immense knowledge and expertise into developing Australia's own protein-based, non-mRNA vaccine for COVID-19.   This is an information packed episode, in which Prof. Petrovsky shares with us his views and knowledge on the technicalities of his vaccine and the mRNA alternatives that have been made available to the public. Paul Vallejo also joins us on this episode to provide his intellect and knowledge on the COVID period.     Contact or follow Prof. Petrovsky at: https://www.linkedin.com/in/petrovsky   Hosted by: ·        Adam Zahra - One Nation candidate for Macarthur (Federal) and Campbelltown (NSW) https://www.facebook.com/AdamZahra.PHON https://www.instagram.com/zahra4campbelltown/   ·        Steven Tripp – One Nation candidate for Warringah and NSW Upper House candidate https://www.facebook.com/ExCandidate.Steven https://twitter.com/RealStevenTripp https://spectator.com.au/author/steven-tripp/ ·        SPECIAL GUEST HOST – Paul Vallejo https://www.linkedin.com/in/paul-g-vallejo-493164 http://savvey.com/stopthisshit/redpill/Are%20we%20following%20the%20science%20v2.pdf   Follow us on: Spotify: https://open.spotify.com/show/4GIXhHBogM1McL5EPGP3DT Rumble: https://rumble.com/user/ExCandidates Facebook: https://www.facebook.com/ExCandidates/ Instagram: https://www.instagram.com/excandidates/ Twitter: https://twitter.com/ExCandidates Gab: https://gab.com/ExCandidates Gettr: https://gettr.com/user/excandidates YouTube: https://www.youtube.com/@excandidates Apple Podcasts: https://podcasts.apple.com/us/podcast/the-ex-candidates/id1631685864 Google Podcasts: https://podcasts.google.com/feed/aHR0cHM6Ly9hbmNob3IuZm0vcy85ZWQ1NGMzMC9wb2RjYXN0L3Jzcw Amazon Music: https://music.amazon.com/podcasts/f6abb085-cb79-411b-958f-e7e89274332f/the-excandidates Stitcher: https://www.stitcher.com/show/the-ex-candidates   Please share and spread the word!   #AusPol #nswpol #interview #podcast #politics #covid #pandemic #vaccines #royalcommission #petrovsky

Professor Nikolai Petrovsky is an accomplished immunologist, vaccine developer, and clinical researcher with decades of experience in his field. He holds a double degree in medicine and surgery and completed his PhD in immunology. He has also contributed over 220 peer-reviewed articles to academic journals. In 2002, Professor Petrovsky founded Vaxine, an Australian biotech company specialising in vaccine development, which developed a COVID-19 vaccine called COVAX-19 which was authorised for emergency use in Iran. In this episode of BASED, Professor Petrovsky shares his expertise in vaccine tech and viruses and his views on Australia's COVID-19 pandemic response.

GUEST OVERVIEW: Nikolai Petrovsky is Professor of Medicine at Flinders University, Director of Endocrinology at Flinders Medical Centre and Research Director of Vaxine, an Adelaide-based biotechnology company focused on vaccine development. He has been awarded over 50 million dollars from the US National Institutes of Health for his vaccine research. He has authored over 200 peer-reviewed research papers and is an inventor on multiple vaccine patents. In 2020, he developed the Covax-19/SpikoGen® vaccine against COVID-19 that in October 2021 received authorization in Iran, making it the first recombinant protein Covid-19 vaccine in the world to receive regulatory approval, and the first Australian-developed human vaccine in the last 40 years to achieve approval.

Episode 351... The storm of new punk music continues! A brand new one from Seattle's NIGHTFEEDER. Hands down going to be one of the best releases (per Bros Grim standards) this year. Some Bros classics mixed in. Enjoy!Download or stream from your smart device here (iTunes and Google Podcasts as well):BROS GRIM 351!!!!!!Airing Wednesdays 7pm PST on PUNK ROCK DEMONSTRATION. Also Fridays and Saturdays 7pm PST on RIPPER RADIO.Send us stuff  to brothersgrimpunk@gmail.com.Punk your face off...Seattle And Now We Die 0:54 Nightfeeder Cut All of Your Face OffJapan 悪夢 2:04 COLONY·DROP ZakuVA SELF-INFLICT "Get In Line" 1:18 Mendeku Diskak/Not For The Weak Recs "s/t" 7"Vermont Beetlejuiced 1:03 The Path Dies ScreamingBros Intro Song by Jeff from Loopy Scoop TapesWaylon Jennings - (bkgrd) Are you sure Hank done it this way 2:56Dry Heaves 1:35 D.R.I. (1992) DefinitionPerdido 1:13 TOTÄLICKERS Totälickers "Ansietät"Not This Time 2:32 Total Massacre Give Sweatshops the Boot Vol. 1Lost In Hollywood 1:37 Time Again The Stories Are TrueVancouver, BC 2:17 The Smugglers Dirty Windshields The SoundtrackTHE SPACE CADETS -(bkgrd) Rockin' with the Space Cadets 3:45Oakland You're Next 1:44 Repo Man DemonstrationAustin Stockholm System 1:01 Dead Zone Mad Minute EPBrooklyn Smokescreen Reality 2:06 Vaxine LP PROMO TOUR TAPE 2022Boston For Them Mincers 1:27 ROTBUS No Time For Fun Vol. 8 [NTR 330]Barcelona Cicatrices 2:38 Lumpen CorrupciónDeaths Kiss (bkgrd) 2:16 Years of Aggression Unknown AlbumSLC City of Dis My Name is.. 1:24 Betty Death to PowerviolenceSLC fake 0:43 total cereal Total Cereal split with  Huele A MierdaSan Diego Summary Execution Via Firing Squad 1:30 Intercom 5 Track DemoDallas SPEED DEMON 1:06 ZOO FIELD TRIP 2 DA ZOOSo Cal Every Man for Himself 1:17 Repeat Offender Promo 2022Van BC Nowhere To Hide 1:55 UPPER RANKS The Mighty Have Fallen The Fugitives - (bkgrd) The Fugitive ~ Surf Instro 3:05Mark's Ark 1:42 Guttermouth Teri YakimotoRun in a Circle 1:30 The Old-timers SOLI DEO GLORIAWake the Dead 1:43 The Filthy Cheaters Wake the DeadSpace Dick 0:55 Joe Billy 2021 Bandcamp SingleBeer & Pogo 1:32 Rpm Seni avaldamata loodLook At Me 2:09 Buddy Holly Buddy HollyDelightful as Always 0:31 INFLUENCER Collection INoose 1:48 Vardagshat Vintersömn (winter sleep)Asymptomatic Idiot 0:15 Atrophic Decay Asymptomatic IdiotSeen Better Days 1:19 Caustic Agent Caustic Agent - Demo 2021Give Up Your Boots 1:47 All City Boot Boys VigilanteCareer Opportunities 1:53 The Clash The ClashGermany Komfortzone 1:34 Pisse Lambada

James Arthur shares his project Vaxine.io, an Elixir layer built on top of a CRDT based distributed Erlang database called Antidote DB. We cover what CRDTs are and introduce how they work. We learn more about Antidote DB, the CURE protocol and especially the Vaxine.io project that adds Ecto types and makes it more approachable to Elixir applications. As applications become more global, the need for strongly consistent distributed writes becomes much more important. Show Notes online - http://podcast.thinkingelixir.com/103 (http://podcast.thinkingelixir.com/103) Elixir Community News - https://www.elixirconf.eu/talks/typecheck-effortless-runtime-type-checking/ (https://www.elixirconf.eu/talks/typecheck-effortless-runtime-type-checking/) – Marten shared an update on the TypeCheck project from ElixirConf.EU (June 9-10) - https://podcast.thinkingelixir.com/72 (https://podcast.thinkingelixir.com/72) – Episode with Martin about TypeCheck - https://twitter.com/elixirphoenix/status/1532707770415325185 (https://twitter.com/elixirphoenix/status/1532707770415325185) - https://twitter.com/wojtekmach/status/1532662628077785088 (https://twitter.com/wojtekmach/status/1532662628077785088) – Screenshot showing the single-file LiveView page - https://github.com/wojtekmach/mixinstallexamples/blob/main/phoenixliveview.exs (https://github.com/wojtekmach/mix_install_examples/blob/main/phoenix_live_view.exs) - Mix Install Examples - Phoenix LiveView app in ~70 LOC (Mix Install Examples - Phoenix LiveView app in ~70 LOC) - https://twitter.com/polvalente/status/1532439823964946432 (https://twitter.com/polvalente/status/1532439823964946432) – New Nx library called nx-signal was shared by the author, Paulo Valente - https://github.com/polvalente/nx-signal (https://github.com/polvalente/nx-signal) - https://twitter.com/josevalim/status/1533136904736198656 (https://twitter.com/josevalim/status/1533136904736198656) – José's cryptic tweet about Torchvision, ONNX, and a LiveView app - https://pytorch.org/vision/stable/index.html (https://pytorch.org/vision/stable/index.html) – Torchvision docs - https://onnx.ai/ (https://onnx.ai/) – ONNX a format for transporting trained machine learning models - https://github.com/thehaigo/live_onnx (https://github.com/thehaigo/live_onnx) – LiveOnnx project that combines the previous things with Axon and LiveView - https://github.com/oestrich/aino (https://github.com/oestrich/aino) – Aino released 0.5 - https://twitter.com/ericoestrich/status/1533995968793919488 (https://twitter.com/ericoestrich/status/1533995968793919488) – Eric explained v0.5 Aino changes - https://twitter.com/josevalim/status/1533907809942880261 (https://twitter.com/josevalim/status/1533907809942880261) – José Valim tweeted a new graphic, teasing something new in Nx land. - https://twitter.com/josevalim/status/1534120503182602240 (https://twitter.com/josevalim/status/1534120503182602240) – José mentioned that there are 3 major announcements this month starting at ElixirConfEU. Stay tuned! Do you have some Elixir news to share? Tell us at @ThinkingElixir (https://twitter.com/ThinkingElixir) or email at show@thinkingelixir.com (mailto:show@thinkingelixir.com) Discussion Resources - https://vaxine.io (https://vaxine.io) – Vaxine.io website - https://antidotedb.eu (https://antidotedb.eu) – Antidote DB website - https://crdt.tech (https://crdt.tech) – CRDT information website - https://vaxine.io/tech/how-it-works (https://vaxine.io/tech/how-it-works) - https://github.com/vaxine-io (https://github.com/vaxine-io) - https://github.com/AntidoteDB/antidote (https://github.com/AntidoteDB/antidote) – Erlang project by a different group "A planet scale, highly available, transactional database built on CRDT technology" - https://www.antidotedb.eu/ (https://www.antidotedb.eu/) - https://github.com/vaxine-io/vaxine (https://github.com/vaxine-io/vaxine) - https://github.com/vaxine-io/vax (https://github.com/vaxine-io/vax) – Data access library and Ecto integration - https://github.com/vaxine-io/examples (https://github.com/vaxine-io/examples) – Example and demo apps - https://www.foundationdb.org/ (https://www.foundationdb.org/) - https://riak.com/index.html (https://riak.com/index.html) - https://www.cockroachlabs.com/ (https://www.cockroachlabs.com/) - https://en.wikipedia.org/wiki/CockroachDB (https://en.wikipedia.org/wiki/CockroachDB) - https://supabase.com/ (https://supabase.com/) - https://lunar.vc/ (https://lunar.vc/) Guest Information - https://twitter.com/VaxineIO (https://twitter.com/VaxineIO) – Vaxine.io on Twitter - https://github.com/vaxine-io/ (https://github.com/vaxine-io/) – Vaxine Github Organization - https://vaxine.io (https://vaxine.io) – Vaxine.io website - https://vaxine.io/blog (https://vaxine.io/blog) – Blog Find us online - Message the show - @ThinkingElixir (https://twitter.com/ThinkingElixir) - Email the show - show@thinkingelixir.com (mailto:show@thinkingelixir.com) - Mark Ericksen - @brainlid (https://twitter.com/brainlid) - David Bernheisel - @bernheisel (https://twitter.com/bernheisel) - Cade Ward - @cadebward (https://twitter.com/cadebward)

Gabor ist Bioinformatiker.Er ist geimpft, allerdings mit einem Impfstoff der in Deutschland nicht akzeptiert wird. Also er hat sich dann noch mal impfen lassen mit dem amerikanischen Impfstoff.Mehr braucht man eigentlich dazu nicht sagen. Oder?Wir debattieren über eine der skurrilsten und schrecklichsten Kapitel des 21. Jahrhunderts. Mitten in irgendwelchen Wellen von irgendwelchen möchtegern Pandemien. Wenn man genau hin hört und zwischen die Zeilen hört, dann wird die Absurdität spätestens in der zweiten Folge die wir ein paar Monate später aufzeichnen deutlich. Ich treffe Gabor in München. Gabor pendle zwischen Wien und München. Ich stelle ein paar naive und vielleicht blöde Fragen. Da ist keine blöden Fragen gibt...Die Entwicklung von Impfstoffen erklärt anhand von ökonomischen Rankings... Der Pharmamarkt, den Gabor sehr gut kennt, da er auch in Amerika schon dafür tätig war. Messenger RNA, Aminosäuren, Reaktionen von Vaxine,...Zu Hause bleiben, Netflix schauen und sich einen runterholen, Gabors Tipp :-) 

Vaccine mandates have questionable legitimacy and fly in the face of half a century of sound vaccination policy. The current ‘vaccines' on the market particularly the mRNA ones are experimental therapies with no long term safety data.That's not the view of a so-called “anti-vaxxer”, but Australian vaccine developer Professor Nikolai Petrovsky who outlines his concerns in episode 8 of Conservative One: Pandemic Unmasked.Prof. Petrovsky is the Director of Endocrinology at Flinders Medical Centre with a conjoint position as Professor of Medicine at Flinders University. He is also vice-president and secretary-general of the International Immunomics Society. Active in diabetes, endocrinology and vaccine research, he is the founder of Vaxine, a company funded by the US National Institutes of Health to develop novel vaccine technologies. In 2009 Vaxine won the AMP Innovation Award at the Telstra Business Awards and Australia's Coolest Company Award from Australian Anthill Magazine. Prof. Petrovsky has developed vaccines against Influenza, Hepatitis B, Sting Allergy, Malaria, Japanese Encephalitis, Rabies and HIV, has authored over 90 papers and chapters and is a regular invited speaker at international vaccine conferences.The podcast is now powered by The Good Sauce conservative news site which can be found at goodsauce.news More podcast episodes from Conservative One can be found at www.georgechristensen.com.au/podcast

Professor Nikolai Petrovsky invented SPIKOGEN (formerly called Covax-19) which has now rolled out to millions of people with zero deaths, zero cases of myo/pericarditis, and zero cases of thrombosis. Such a remarkable adverse event profile is, according to the professor, absolutely normal in traditional vaccine development but has been forgotten in a sea of adverse events around the world. Now approved in New Zealand as a travel vaccine, the professor joined me to discuss a massive range of topics including the science behind spike proteins, C-19 variants, truth in efficacy reporting, natural immunity, viral attenuation, and the future for his vaccine SPIKOGEN. Nikolai is the Director of Endocrinology at the Flinders Medical Centre (South Australia), Professor of Medicine at Flinders University (South Australia), Vice President of the International Immunomics Society, founder of Vaxine and creator of SPIKOGEN. Watch this episode: https://youtu.be/0nGLwBuJnLI --------------------------------------- DISCERNABLE Our Private Community: discernable.locals.com The Crew Mailing List: https://discernable.io/crew The Podcast: http://discernable.io/listen The Video Archive: https://www.youtube.com/discernable & https://odysee.com/@discernable Our Town Hall on Ethics with Acting Senior Sergeant Krystal Mitchell: https://www.crowdcast.io/e/learnethics PROFESSOR NIKOLAI PETROVSKY https://twitter.com/vaxine_news https://vaxine.net --------------------------------------- 1:47 SPIKOGEN receives a provisional determination from Australia's Therapeutic Goods Administration (TGA) 3:25 How does SPIKOGEN compare to NovaVax? 6:22 SPIKOGEN approved in New Zealand 14:17 The safety of protein based vaccines 15:10 Adverse events with protein vaccines 17:22 The scientific data on SPIKOGEN 23:30 The historic crowdfunding of a vaccine 25:54 What are ‘breakthrough infections'? 30:09 Protein vaccines can be as fast as mRNA therapies 33:26 How to make spike proteins for different variants – genomic sequences 36:43 Injecting ready made spike proteins vs injecting mRNA 39:39 The different types of spike proteins 40:59 Why are mRNA vaccines causing thrombosis, myocarditis, pericarditis etc? 45:34 How does natural immunity compare to vaccinal immunity? 52:08 Omicron variant is not necessarily ‘less severe' – we don't know yet 54:17 Why viral attenuation is a myth 59:54 Nikolai Petrovsky vs Geert Vanden Bossche – antibody dependent enhancement 1:03:27 Population wide vaccination vs vulnerable vaccination 1:07:47 Should we vaccinate young children with SPIKOGEN? 1:09:56 The problem with comparing Covid-19 to influenza 1:16:46 SPIKOGEN is NOT a life-long prescription 1:22:30 How doctors used to weigh up risk vs benefit 1:25:46 COVAX is NOT COVAX-19…this is the difference 1:26:57 The professor took his own vaccine but it wasn't good enough for government 1:29:53 The financial deal between Vaxine and Discernable to promote SPIKOGEN 1:30:18 EOI for SPIKOGEN clinical trials

Nearly two years after Covid-19 was first detected in Wuhan, the world is still very much in a pandemic. The toughest phase may behind us, but we are still faced with the possibility of new variants of concern, waning immunity and vaccine evasion. As first-generation vaccines start to show their weaknesses, next-generation vaccines are becoming more and more important. While hundreds of vaccines are in the pipeline, there are a few frontrunners and other interesting candidates that might be meaningful additions to our Covid vaccine armamentarium. Experts discuss the current status of a number of protein-based vaccines including candidates from Novavax, Vaxine, Clover, GSK/Sanofi and others. DNA vaccines are also still an attraction with the first authorization for Zydus Cadila in India. Other mRNA vaccines might offer meaningful differentiation, while vaccines targeting the S and N protein might also have greater importance when it comes to tackling future variants. While nasal and oral vaccines seem appealing for the prevention of infection and transmission, they also have some inevitable hurdles to overcome and are still a long way off materializing. Experts discuss future manufacturing hurdles that will require greater global collaboration to achieve future vaccine production and distribution goals. Finally, experts discuss the current global status so far and forecasts for exiting the pandemic state and entering a livable endemic.  Expert Guests: -- Reynald Castaneda is the Clinical Trials Editor of GlobalData Media in London, covering drug development for investors and the pharmaceutical industry. -- Dr Maria Elena Bottazzi is the Associate Dean, National School of Tropical Medicine and Professor of Pediatrics (Tropical Medicine) and Molecular Virology and Microbiology at Baylor College of Medicine, Texas, US. She is a leading expert in vaccine development and tropical diseaes. -- Dr Deborah Fuller is a Professor of Microbiology at The University of Washington School of Medicine. A veteran vaccinologist and researcher, she has been working on vaccine development for the last 30 years with specific research around DNA and RNA technologies.  -- Dr Shabir Madhi is Dean of the Faculty of Health Sciences and Professor of Vaccinology at the University of the Witwatersrand, Johannesburg, South Africa. He is also the co-founder of the African Leadership Initiative for Vaccinology Expertise (ALIVE). -- Dr Nikolai Petrovsky is Professor of Medicine, Flinders University, Adelaide, Australia and vice-president and secretary-general of the International Immunomics Society. He is the founder of vaccine biotech, Vaxine, which has a protein based vaccine for Covid-19 in its pipeline. -- Dr Monica Gandhi is Professor of Medicine and Associate Division Chief (Clinical Operations/Education) of the Division of HIV, Infectious Diseases, and Global Medicine at University California San Francisco/San Francisco General Hospital. -- Dr Prashant Yadav is a Senior Fellow at the Center for Global Development and Affiliate Professor of Technology and Operations Management at INSEAD. Yadav has with governments and global organizations to improve medical product supply chains. Previous roles include Strategy Leader-Supply Chain at the Bill & Melinda Gates Foundation and Chair of the Market Dynamics Advisory Group of the Global Fund. -- Dr. Nadia Sam-Agudu is Associate Professor of Pediatrics (Immunology/Infectious Diseases) at the University of Maryland School of Medicine and Senior Technical Advisor at the Institute of Human Virology Nigeria. She conducts public health and implementation research in maternal and child health, with a focus on HIV and other major infectious diseases in African countries.

Most people are focused on the mRNA vaccines ( Pfizer-BioNTech & Moderna) or the viral-vector vaccines, like J&J, but many researchers and companies are working on protein subunit vaccines for COVID-19. Dr. Petrovsky and his company, Vaxine, created a protein subunit vaccine for COVID-19 that was tested in randomized controlled trials in Iran and just recently approved for use there. ( I believe it is the first protein subunit vaccine approved for use anywhere.) In this podcast he will discuss how it was made, efficacy and safety results, possible side effects, where it is currently available, if it is easily updated and more. In the second half of the podcast he shares his experience of the political situation in Australia. I can't comment on that, because I don't know exactly what is happening in Australia, but it sounds concerning. Dr. Petrovsky is a doctor, vaccine researcher and director of endocrinology at Flinders Medical Centre in Australia. He is vice-president and secretary-general of the international immunomics society. He is the founder and chairman of Vaxine, a company funded by the NIH to create new vaccine technology. Dr. Petrovsky has developed vaccines for influenza, hepatitis b, malaria, rabies and more. He is author of over 90 papers and book chapters. To contact Dr. Eeks, do so through bloomingwellness.comTo  listen to her comedic parody/audiobook on the sleazy side of the wellness industry, check out Yours in Wellness, Krystal Heeling on Amazon.Or you can listen to it from Google Play or Walmart!Or follow her on Instagram here.Twitter here.Or Facebook here.Subcribe to her newsletter here!

As the world tries to take a hold over the delta variant, we're all watching and waiting to see if the virus is going to evolve into something new. There are fears that natural selection could potentially yield a new variant that will completely escape all of our current vaccines. While these scenarios are hypothetical, experts discuss the need to be vigilant and prepared without unnecessary panic. Experts unpack the virus' evolution so far into delta and how that has impacted our goals for herd immunity. They talk about the possibilty for delta to change into a variant more transmissible or virulent, and how potentially leaky vaccines might impact or enhance the virus' evolutionary path. In August, Joe Rogan highlighted a paper on his podcast "The Joe Rogan Experience," which raised public concern that our current vaccines are potentially encouraging new potent variants to emerge. The author of that paper, Professor Andrew Read, comes on to clarify his research in chickens and where certain extrapolations can and can't be made. Meanwhile, experts discuss the possibility of vaccine pressure and the need for new vaccines and which types of vaccine development strategies might better help us get ahead of the virus' curve.  Expert Guests: -- Dr Shabir Madhi Shabir Madhi is Dean of the Faculty of Health Sciences and Professor of Vaccinology at the University of the Witwatersrand, Johannesburg, South Africa. He is also the co-founder of the African Leadership Initiative for Vaccinology Expertise (ALIVE). -- Dr Jeffrey Morris is Professor of Biostatistics and Director, Biostatistics Division at the University of Pennsylvania, US. His research focuses on developing quantitative methods to extract knowledge from biomedical big data and he set up a blog dedicated to issues concerning the Covid-19 pandemic. -- Dr Nikolai Petrovsky is Professor of Medicine, Flinders University, Adelaide, Australia and vice-president and secretary-general of the International Immunomics Society. He is the founder of vaccine biotech, Vaxine, which has a protein based vaccine for Covid-19 in its pipeline. -- Dr Monica Gandhi is Professor of Medicine and Associate Division Chief (Clinical Operations/Education) of the Division of HIV, Infectious Diseases, and Global Medicine at University California San Francisco/San Francisco General Hospital.

As governments around the world try to get their countries and economies back on track, they are starting to desperately implement a number of vaccine policies that have sometimes been questioned by society and scientists. In this episode, experts discuss the rationale around boosters, who should get them, when they are the most effective and the problems around offering third doses to individuals when many vulnerable people around the globe are still fighting for their first. Experts also talk about mandates and the debate around forcing the previously infected to be fully immunized when the data suggests otherwise. They also discuss possible mandates for children and schools, vaccine passports to live general life and cross borders as well as different countries discriminating against which vaccines are acceptable for a passport. Finally, experts talk about whether it makes scientific sense to implement such strict mandates at this stage of the pandemic given the shifting understanding around how these vaccines are actually working among communities. With the current problem of global vaccine inequity, experts question whether such mandates implemented by rich countries are ethical and fair. Expert guests: -- Dr Monica Gandhi is Professor of Medicine and Associate Division Chief (Clinical Operations/Education) of the Division of HIV, Infectious Diseases, and Global Medicine at University California San Francisco/San Francisco General Hospital. -- Dr Nikolai Petrovsky is Professor of Medicine, Flinders University, Adelaide, Australia and vice-president and secretary-general of the International Immunomics Society. He is the founder of vaccine biotech, Vaxine, which has a protein based vaccine for Covid-19 in its pipeline. -- Dr Jeffrey Morris is Professor of Biostatistics and Director, Biostatistics Division at the University of Pennsylvania, US. His research focuses on developing quantitative methods to extract knowledge from biomedical big data and he set up a blog dedicated to issues concerning the Covid-19 pandemic. -- Dr. Nadia Sam-Agudu is Associate Professor of Pediatrics (Immunology/Infectious Diseases) at the University of Maryland School of Medicine, and Senior Technical Advisor at the Institute of Human Virology Nigeria. She conducts public health and implementation research in maternal and child health, with a focus on HIV and other major infectious diseases in African countries. -- Dr Miguel O'Ryan is Professor of Microbiology and Mycology, Faculty of Medicine at the University of Chile, where is also Director of International Affairs. His research focuses on molecular and clinical aspects of enteric disease, pediatric vaccines and infection of the immunocompromised host. -- Dr Andrew Read is Professor of Biology and Entomology at PennState University, US. His research specializes in the ecology and evolutionary genetics of infectious disease, which includes the impact of vaccination on virus evolution.

Vaccination in children has fueled a global expert debate specifically around the risk benefit consideration that some may find acceptable and others may find questionable. While children were largely protected from the virus early on in the pandemic, we've come to a point where children are getting sick, some of them severely ill and dying. Experts discuss the changing risks of Covid in kids and how the benefits of vaccination in kids measure up versus potential adverse events. We first look at inactivated vaccines, which are now the most used vaccines in children (as young as 2 years of age) and we take a special deep dive into Chile's rationale for its large scale vaccination drive to get kids back into school. mRNA vaccines are also starting to get rolled out with Pfizer just receiving a US authorization in kids aged 5-11, and experts discuss the risk benefits and greater unknowns of this new technology, particularly around the nuance of dosing, Experts discuss the overall rationale for vaccination when looking at efficacy, safety and potential mechanistic concerns. Vaccinating kids and its overall impact on this pandemic remains debated, although perhaps not in Africa, where children may be the most at need of vaccination to reach global herd immunity, yet stand to be at the end of the queue. Meanwhile, as the issue around pregnancy continues to generate vaccine hesitancy, experts discuss new available data that speaks to the the risk/benefit profile in pregnant women and women wanting to conceive. Expert Guests -- Dr Miguel O'Ryan is Professor of Microbiology and Mycology, Faculty of Medicine at the University of Chile, where he is also Director of International Affairs. His research focuses on molecular and clinical aspects of enteric disease, pediatric vaccines and infection of the immunocompromised host. -- Dr. Nadia Sam-Agudu is Associate Professor of Pediatrics (Immunology/Infectious Diseases) at the University of Maryland School of Medicine, and Senior Technical Advisor at the Institute of Human Virology Nigeria. She conducts public health and implementation research in maternal and child health, with a focus on HIV and other major infectious diseases in African countries. -- Dr Nikolai Petrovsky is Professor of Medicine, Flinders University, Adelaide, Australia and vice-president and secretary-general of the International Immunomics Society. He is the founder of vaccine biotech, Vaxine, which has a protein based vaccine for Covid-19 in its pipeline. -- Dr Maria Elena Bottazzi is the Associate Dean, National School of Tropical Medicine and Professor of Pediatrics (Tropical Medicine) and Molecular Virology and Microbiology at Baylor College of Medicine, Texas, US. She is a leading expert in the field of vaccine development and tropical diseases. -- Dr Deborah Fuller is a Professor of Microbiology at The University of Washington School of Medicine. A veteran vaccinologist and researcher, she has been working on vaccine development for the last 30 years with specific research around DNA and RNA technologies.

With around 7 billion doses administered, the vaccines have largely been proven safe, but there are still major concerns around rare serious side-effects and long term safety unknowns. Experts discuss how safety events have been picked up via public reporting systems -- which have been both a help and a hindrance for the safety discussion -- and how they are being further analyzed. Experts breakdown real world data and the occurrence of rare serious adverse events including VITT (with the adenoviral vector vaccines) and myocarditis (with the mRNA vaccines). While the newer modalities have led to a few surprise fatalities, the inactivated viral vaccines remain clear of fatal serious events and experts discuss what risk ratio is generally acceptable in a deadly pandemic. Experts also discuss extreme safety alarm being perpetuated by social media, particularly the claim that vaccines are killing more people than they are saving. They stress the need for better public communication and education, whilst it is important to vet public sources that may be overdramatizing certain risks by promoting flawed analyses. Expert Guests: -- Dr Jeffrey Morris is Professor of Biostatistics and Director, Biostatistics Division at the University of Pennsylvania, US. His research focuses on developing quantitative methods to extract knowledge from biomedical big data and he set up a blog dedicated to issues concerning the Covid-19 pandemic. -- Dr Nikolai Petrovsky is Professor of Medicine, Flinders University, Adelaide, Australia and vice-president and secretary-general of the International Immunomics Society. He is the founder of vaccine biotech, Vaxine, which has a protein based vaccine for Covid-19 in its pipeline. -- Dr Maria Elena Bottazzi is the Associate Dean, National School of Tropical Medicine and Professor of Pediatrics (Tropical Medicine) and Molecular Virology and Microbiology at Baylor College of Medicine, Texas, US. She is a leading expert in the field of vaccine development and tropical diseases. -- Dr Miguel O'Ryan is Professor of Microbiology and Mycology, Faculty of Medicine at the University of Chile, where is also Director of International Affairs. His research focuses on molecular and clinical aspects of enteric disease, pediatric vaccines and infection of the immunocompromised host.

Since the last episode in February, a lot has happened with the vaccination rollout -- so we're back for a few more episodes. But we've changed our name from The CoVax Files to The Vax Files, which was was done mainly to avoid any confusion with GAVI/WHO's COVAX facility and also to maintain our independence from any official organization. As we approach the end of 2021 and almost 7 billion administered vaccine doses, we now have a good chunk of real world effectiveness data available. During this episode, experts walk us through some important datasets that can speak to how the vaccines have been working, with particular nuances around the emergence of the highly transmissible Delta variant. Experts take a deep dive into real world evidence data in different countries to elucidate overall protection, antibody waning, protection against severe disease and death as well as the likelihood of transmission when vaccinated. Finally, experts discuss the dangers of misinterpreting headline or summary data, which has been a regular occurrence in the media and social media during this pandemic. Expert Guests: -- Dr Jeffrey Morris is Professor of Biostatistics and Director, Biostatistics Division at the University of Pennsylvania, US. His research focuses on developing quantitative methods to extract knowledge from biomedical big data and he set up a blog dedicated to issues concerning the Covid-19 pandemic. -- Dr Nikolai Petrovsky is Professor of Medicine, Flinders University, Adelaide, Australia and vice-president and secretary-general of the International Immunomics Society. He is the founder of vaccine biotech, Vaxine, which has a protein based vaccine for Covid-19 in its pipeline. -- Dr Maria Elena Bottazzi is the Associate Dean, National School of Tropical Medicine and Professor of Pediatrics (Tropical Medicine) and Molecular Virology and Microbiology at Baylor College of Medicine, Texas, US. She is a leading expert in the field of vaccine development and tropical diseases. -- Dr Andrew Read is Professor of Biology and Entomology at PennState University, US. His research specializes in the ecology and evolutionary genetics of infectious disease, which includes the impact of vaccination on virus evolution.

Professor Nikolai Petrovsky is the Director of Endocrinology (Flinders Medical Centre), Professor of Medicine (Flinders University), Vice President of the International Immunomics Society, Founder of Vaxine and the creator of COVAX-19 and Spikogen. He joins us for the second time in the follow up interview to discuss the progress of his traditional protein vaccine (COVAX-19/Spikogen), the medical ethics of mandating vaccines, a comparison of vaccine types, concerns with mRNA and adenoviral vector vaccines, vaccine adverse event incidence rates, and the scientific errors being made by politicians conflating community protection with individual protection. As a vaccine creator, Professor Petrovsky is very vocal on his LinkedIn account against the mandating of vaccines, especially with no scientific justification. Some may miss parts in this interview where he nonchalantly drops bombshells regarding his now approved protein vaccines. It may be the case that we have successfully created a traditional vaccine, right here in Australia, that completely outperforms the major products on the market today AND has a significantly lower adverse event rate. As data is released showing the performance of his and other competitor protein vaccines (such as NovaVax) it will raise sticky questions for Australian Health Minister Greg Hunt MP: 1. Why has the Australian government refused to engage with Australian vaccine creators? 2. Why has CSL refused to cooperate with Australian vaccine companies? 3. What are in those secret commercial contracts with Pfizer et al? 4. Are there clauses that prevent competition and consideration of products that are actually safer for the Australian population? Watch this episode on Youtube: https://youtu.be/9x2ieHuj8zU ---------------------------------- PROFESSOR NIKOLAI PETROVSKY www.linkedin.com/in/petrovsky https://vaxine.net DISCERNABLE Our Private Community: discernable.locals.com The Crew Mailing List: https://discernable.io/crew The Video Archive: https://www.youtube.com/discernable The Podcast: http://discernable.io/listen ---------------------------------- 2:04 Should people be concerned about current Covid-19 vaccines? 7:07 Why mandates are not scientifically justified. 10:37 The transmissibility of Covid-19/Sars-Cov2 13:02 Current vaccines won't get us ‘back to normal' 15:50 Current vaccines do not provide community benefits, only individual benefits 18:59 CSL refuses to cooperate with Australian vaccine creators 23:07 Big pharma has zero liability 26:49 Liability waivers are given selectively 30:13 Government contracts are shrouded in secrecy 33:16 The mass silencing of concerned individuals in Australia 36:32 The silence from medical professional associations 38:54 The government is downplaying vaccine adverse events 44:42 What are normal rates of adverse events from traditional vaccines? 48:48 Should children be vaccinated against Covid-19? 55:53 What is the COVAX-19 vaccine? 59:30 What happened in the clinical trials? 1:02:24 COVAX-19 phase 3 trial data compared to the other vaccines 1:04:03 COVAX-19 approved and rolling out now 1:05:26 Will COVAX-19 be approved in western countries? 1:07:27 The science behind COVAX-19 1:08:15 MRNA vaccines vs protein-based vaccines 1:13:05 Adjuvants used in COVAX-19 1:14:16 Will COVAX-19 need boosters? 1:16:22 BREAKING: Sterilising immunity of COVAX-19 1:20:19 What about natural immunity? 1:25:27 Making your voice heard to defend democracy 1:28:27 The pandemic has exposed failing systems worldwide

پرفسور نیکولای پتروفسکی (Nikolai Petrovsky) یک دانشمند در دانشگاه فلیندرز در آدلاید و مدیر شرکت Vaxine می گوید این شرکت در حال همکاری با یک شرکت ایرانی به نام سیناژن (CinnaGen) برای تولید یک واکسن کروناویروس است. وی می گوید علاوه بر ایران، این شرکت در حال همکاری با چند کشور دیگر برای تولید این واکسن است.

In this final and tenth episode, we'll tackle some of the last lingering questions that we all have around the vaccines and how the future might look as we navigate these uncharted pandemic waters. Experts first discuss new interim datasets from Johnson and Johnson and Novavax, notably their results on preventing severe disease, hospitalizations and deaths, and how they might fit into the vaccine paradigm. We'll break down why some EU countries have made the surprise recent decision not to administer AstraZeneca's vaccine to people over 65. Meanwhile, Russia's Sputnik-V now has a lot more data and we'll see how this vaccine measures up on the global scale of vaccines. Experts discuss vaccine utility in the real world and the debate around infection and transmission, delaying the second dose to get first doses out quicker and mixing different vaccine brands under extenuating circumstances. Safety remains a big question as the media and social media continue to flag individual cases of severe side-effects and deaths, but we'll look at the data and statistics and how to critically think about the overall safety profile of the vaccine (and when not to panic). Finally, this episode will tackle important future questions such as the need to vaccinate children and how things might look as we attempt to get back to being a global community with travel. Expert Guests: -- Dr Jeffery Morris is Professor of Biostatistics and Director, Biostatistics Division at the University of Pennsylvania. His research interests focus on developing quantitative methods to extract knowledge from biomedical big data. -- Dr Monica Gandhi is Professor of Medicine and Associate Division Chief (Clinical Operations/Education) of the Division of HIV, Infectious Diseases, and Global Medicine at University California San Francisco/San Francisco General Hospital. -- Dr Gayani Tillekeratne is Assistant Professor of Medicine and Assistant Research Professor of Global Health at Duke University. She was a co-investigator on the clinical trials of both Johnson & Johnson and AstraZeneca's vaccine in the US. -- Dr Nikolai Petrovsky is Professor of Medicine, Flinders University, Adelaide and vice-president and secretary-general of the International Immunomics Society. He is the founder of vaccine biotech, Vaxine, which has a protein based candidate in early development for Covid-19. -- Dr Saul Faust is Professor of Paediatric Immunology and Infectious Diseases and Director of the Southampton NIHR Wellcome Trust Clinical Research Facility at the University of Southhampton. He is heavily involved in UK paedatric vaccine trials. -- Dr Mary-Louise McLaws is Professor of Epidemiology at the University of New South Wales and is also a member of the World Health Organization (WHO) Health Emergencies Program Experts Advisory Panel for Infection Prevention and Control Preparedness, Readiness and Response to COVID-19.

In this ninth episode, we'll tackle the different conundrums we face with the emergence of new and highly transmissible SARS-COV-2 variants. Get ready to delve into some thought provoking scientific concepts when it comes to how this virus appears to be evolving and where we stand with our current and future vaccination goals. The episode parses out the most worrisome mutations, how they were able to evolve and why they are such a concern. Experts talk about recent data from Johnson & Johnson and Novavax, which are tell tale signs of the issues we have ahead. They also discuss where our currently authorized vaccines - Pfizer, Moderna, AstraZeneca -- stand to combat the new variants. We'll explore what manufactures are doing to keep up with new mutations and the various challenges in chasing a moving target. While experts agree that this will probably not be a once in a lifetime vaccination, they make comparisons to seasonal influenza and remain debated on how often we might need to revaccinate. Finally, experts discuss the best approach forward with both the vaccines and prudent social behaviors to ensure that we don't lose this pandemic battle due to complacency. Expert Guests: -- Dr Mary-Louise McLaws is Professor of Epidemiology at the University of New South Wales and is also a member of the World Health Organization (WHO) Health Emergencies Program Experts Advisory Panel for Infection Prevention and Control Preparedness, Readiness and Response to COVID-19. -- Dr Monica Gandhi is Professor of Medicine and Associate Division Chief (Clinical Operations/Education) of the Division of HIV, Infectious Diseases, and Global Medicine at University California San Francisco/San Francisco General Hospital. -- Dr Nikolai Petrovsky is Professor of Medicine, Flinders University, Adelaide and vice-president and secretary-general of the International Immunomics Society. He is the founder of vaccine biotech, Vaxine, which has a protein based candidate in early development for Covid-19. -- Verity Hill is an evolutionary biologist at the University of Edinburgh and is currently completing her PhD using genomic epidemiology to study the spread of Ebola in West Africa. She has authored a number of papers on the evolution of SARS-COV2 with the world's top researchers in the field.

Professor Nikolai Petrovsky is the Director of Endocrinology at Flinders Medical Centre with a conjoint position as Professor of Medicine at Flinders University. He is Vice-President and Secretary-General of the International Immunomics Society. Nikolai is the founder of Vaxine, a company funded by the US National Institutes of Health to develop novel vaccine technologies. in 2009 Vaxine won the Amp Innovation Award at the Telstra Business Awards and Australia's Coolest Company award from Australian Anthill Magazine. During his career Nikolai has developed vaccines against influenza, hepatitis b, sting allergy, malaria, Japanese Encephalitis, rabies and HIV, and has authored over 90 papers and academic chapters. ------------------------------------------ Watch this episode on Youtube: https://youtu.be/42Z2rztT_Es Nikolai's company Vaxine which developed COVAX-19: https://vaxine.net/ ------------------------------------------ 00:11 Summary of interview 04:00 Zoom starts 05:30 Vaccines can treat almost anything 07:55 How vaccines work against non-infectious diseases 09:40 Human bio engineering and evolution 11:47 Experimental vaccine rollout worldwide 16:07 Making vaccines mandatory is highly inappropriate right now 18:21 Are the mRNA vaccines a true vaccine or simply a ‘therapy'? 19:54 Vaxine has developed a much safer vaccine called COVAX-19 23:52 The side effect profiles of mRNA and viral vector vaccines (Pfizer and AstraZeneca) 28:35 Adjuvents in vaccines like aluminium 29:44 When will COVAX-19 be available? 33:14 Other companies making ‘protein' vaccines 34:05 Sterilising immunity (preventing infection) vs reducing symptoms 35:20 How influenza vaccines will improve 36:27 The eradication of influenza 37:46 Why does social distancing, masks etc prevent Influenza but not COVID-19? 40:23 Cross reactivity between influenza and COVID-19 42:43 Getting a vaccine is better than the getting the infection 46:18 mRNA vaccines are being used to lessen symptoms, not prevent infectivity 48:35 Legal indemnity for vaccine developers

Die ersten Impfungen sind erfolgt, mehrere Vaxine gegen Covid-19 zugelassen. Ein Hoffnungsschimmer. Doch es geht langsam voran, die bisherigen Impfstoffmengen reichen nicht aus, um sehr schnell eine Immunisierung herbeizuführen. Und dann kommt auch noch die Mutation des Virus hinzu. Im Gespräch mit Norbert Lossau, Chefkorrespondent Wissenschaft bei WELT geht es darum, wie der Impfprozess beschleunigt werden kann. Was weiß man darüber, ob die Wirkstoffe zu mischen sind? Wären geringere Impfdosen ausreichend und wie schnell können Forscher auf Mutationen reagieren?

Medical trials are a big part of the research process.